The oral Janus kinase/spleen tyrosine kinase inhibitorASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

Spleen Tyrosine Kinase ◽

Double Blind ◽

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study

British Journal of Dermatology ◽

10.1111/bjd.20690 ◽

2021 ◽

Author(s):

Y. Zhao ◽

L. Wu ◽

Q. Lu ◽

X. Gao ◽

X. Zhu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2013.12.1068 ◽

2014 ◽

Vol 133 (2) ◽

pp. AB404 ◽

Cited By ~ 2

Author(s):

Thomas R.M. Bieber ◽

Diamant Thaci ◽

Neil Graham ◽

Gianluca Pirozzi ◽

Ariel Teper ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Double Blind ◽

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Effects of a topical treatment with spleen tyrosine kinase (SYK) inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a Phase 1a/b randomised double‐blind placebo‐controlled study

British Journal of Clinical Pharmacology ◽

10.1111/bcp.14923 ◽

2021 ◽

Author(s):

Marion C. Dickson ◽

Alexandra Walker ◽

Clive Grattan ◽

Hayley Perry ◽

Nicola Williams ◽

...

Keyword(s):

Tyrosine Kinase ◽

Topical Treatment ◽

Healthy Subjects ◽

Chronic Spontaneous Urticaria ◽

Controlled Study ◽

Spleen Tyrosine Kinase ◽

Cold Urticaria ◽

Double Blind ◽

Double Blind Placebo ◽

Syk Inhibitor

Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase III, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.737 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB199

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Japanese Adult ◽

Double Blind ◽

Janus Kinase Inhibitor

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.12.015 ◽

2020 ◽

Vol 82 (4) ◽

pp. 823-831 ◽

Cited By ~ 19

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Hironobu Kaino ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

Treatment with tralokinumab improves health-related quality of life in adult patients with moderate to severe atopic dermatitis: results from a Phase 2b, randomised, double-blind, placebo-controlled study

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.supp.64 ◽

2018 ◽

Vol 2 ◽

pp. S64

Author(s):

Jonathan I Silverberg ◽

Nana Kragh ◽

Emma Guttman-Yassky ◽

Andreas Wollenberg

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Controlled Study ◽

Health Related Quality ◽

Double Blind ◽

Double Blind Placebo ◽

Related Quality ◽

Health Related

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12081 ◽

2013 ◽

Vol 28 (2) ◽

pp. 192-203 ◽

Cited By ~ 38

Author(s):

C. Mamolo ◽

J. Harness ◽

H. Tan ◽

A. Menter

Keyword(s):

Patient Reported Outcomes ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Patient Reported

Probiotics improve atopic dermatitis in children and adolescents: a double blind, placebo-controlled study.

10.22541/au.158930908.86661145 ◽

2020 ◽

Author(s):

Paula Danielle Santa Maria Albuquerque de Andrade ◽

Jorgete Maria e Silva ◽

Vanessa Carregaro ◽

La s Sacramento ◽

Luciana Roberti ◽

...

Keyword(s):

Atopic Dermatitis ◽

Children And Adolescents ◽

Controlled Study ◽

Double Blind ◽